| 晚期非小细胞肺癌吉非替尼治疗性别与疗效相关性分析 |
| |
| 引用本文： | 杨钰贤,丘希辉,陈志明,庄晓文,张盛奇.晚期非小细胞肺癌吉非替尼治疗性别与疗效相关性分析[J].中华肿瘤防治杂志,2011,18(16):1277-1279. |
| |
| 作者姓名： | 杨钰贤 丘希辉 陈志明 庄晓文 张盛奇 |
| |
| 作者单位： | 汕头大学医学院附属肿瘤医院肿瘤内科,广东汕头,515031 |
| |
| 摘 要： | 目的:探讨吉非替尼对不同性别晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。方法:选择化疗失败的晚期NSCLC患者74例,分为女性组(36例)和男性组(38例),应用吉非替尼进行单药治疗,口服剂量为250 mg/d。分析两组治疗疗效和安全性。结果:女性组和男性组的总有效率(47.2%vs 26.3%,P=0.062)以及中位无进展生存期(7.9个月vs 5.7个月,P=0.093)差异均无统计学意义;而其中女性腺癌患者的有效率(53.8%)与以及中位无进展生存期(10.1个月)明显优于男性鳞癌患者,差异均有统计学意义,P值均<0.05。两组的不良反应相似主要为皮疹和腹泻。结论:对于晚期NSCLC患者,在无检测表皮生长因子受体(EGFR)情况下,合理选择优势人群,应用分子靶向药物吉非替尼治疗,疗效较高,能有助于提高NSCLC临床个体化治疗水平。
|
| 关 键 词： | 吉非替尼 癌 非小细胞肺 女性 男性 疗效 |
Efficacy of gefitinib on advanced non-small cell lung cancer patients with different sex |
| |
| YANG Yu-xian,QIU Xi-Hui,CHEN Zhi-ming,ZHUANG Xiao-wen,ZHANG Sheng-qi.Efficacy of gefitinib on advanced non-small cell lung cancer patients with different sex[J].Chinese Journal of Cancer Prevention and Treatment,2011,18(16):1277-1279. |
| |
| Authors: | YANG Yu-xian QIU Xi-Hui CHEN Zhi-ming ZHUANG Xiao-wen ZHANG Sheng-qi |
| |
| Institution: | YANG Yu-xian,QIU Xi-Hui,CHEN Zhi-ming,ZHUANG Xiao-wen,ZHANG Sheng-qi Department of Oncology,Tumor Hospital,Medical College of Shantou University,Shantou 515031,P.R.China |
| |
| Abstract: | OBJECTIVE:To select dominant crowd in advanced non-small-cell lung cancer(NSCLC) by comparing the efficacy and safety of gefitinib on advanced NSCLC in different gender groups.METHODS: Seventy-four advanced NSCLC patients(36 female and 38 male) who failed in previous chemotherapy perorally received gefitinib 250 mg/d.The efficacy and safety of gefitinib on advanced NSCLC between the two groups was compared.RESULTS: Neither the overall response rate(47.2% vs 26.3%,P=0.062) nor the median progression free sur... |
| |
| Keywords: | gefitinib carcinoma non-small cell lung female male efficacy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
